Refine
Departments, institutes and facilities
Document Type
- Article (43)
- Part of a Book (5)
Year of publication
Language
- English (48)
Keywords
- cytokine-induced killer cells (9)
- immunotherapy (7)
- cytokine-induced killer (CIK) cells (3)
- Bcl-2 (2)
- CIK cells (2)
- apoptosis (2)
- lymphoma (2)
- 2B4 (1)
- CD30+ cells (1)
- CD40, CTLA-4 (1)
Cancer is a complex disease where resistance to therapies and relapses often pose a serious clinical challenge. The scenario is even more complicated when the cancer type itself is heterogeneous in nature, e.g., lymphoma, a cancer of the lymphocytes which constitutes more than 70 different subtypes. Indeed, the treatment options continue to expand in lymphomas. Herein, we provide insights into lymphoma-specific clinical trials based on cytokine-induced killer (CIK) cell therapy and other pre-clinical lymphoma models where CIK cells have been used along with other synergetic tumor-targeting immune modules to improve their therapeutic potential. From a broader perspective, we will highlight that CIK cell therapy has potential, and in this rapidly evolving landscape of cancer therapies its optimization (as a personalized therapeutic approach) will be beneficial in lymphomas.